Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcome and risk factors for recurrence in borderline ovarian tumours.
Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, Yaegashi N, Okamura K, Izutsu T, Sugiyama T, Tanaka T, Kurachi H, Sato A, Tase T, Mizunuma H. Yokoyama Y, et al. Among authors: shoji t. Br J Cancer. 2006 Jun 5;94(11):1586-91. doi: 10.1038/sj.bjc.6603139. Br J Cancer. 2006. PMID: 16685277 Free PMC article.
Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, Nakahara K, Yamada H, Mizunuma H, Yaegashi N, Sugiyama T, Kurachi H, Sato A, Tanaka T. Fujimoto T, et al. Among authors: shoji t. Gynecol Oncol. 2007 Nov;107(2):253-9. doi: 10.1016/j.ygyno.2007.06.009. Epub 2007 Jul 19. Gynecol Oncol. 2007. PMID: 17640720
Identifying prognostic factors in Japanese women with pseudomyxoma peritonei: a retrospective clinico-pathological study of the Tohoku Gynecologic Cancer Unit.
Kojimahara T, Nakahara K, Shoji T, Sugiyama T, Takano T, Yaegashi N, Yokoyama Y, Mizunuma H, Tase R, Satou H, Tanaka T, Motoyama T, Kurachi H. Kojimahara T, et al. Among authors: shoji t. Tohoku J Exp Med. 2011 Feb;223(2):91-6. doi: 10.1620/tjem.223.91. Tohoku J Exp Med. 2011. PMID: 21263209 Free article.
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Shoji T, Takatori E, Omi H, Kumagai S, Yoshizaki A, Yokoyama Y, Mizunuma H, Fujimoto T, Takano T, Yaegashi N, Tase T, Nakahara K, Kurachi H, Nishiyama H, Sugiyama T. Shoji T, et al. Int J Gynecol Cancer. 2011 Jan;21(1):44-50. doi: 10.1097/IGC.0b013e3181ffbe9f. Int J Gynecol Cancer. 2011. PMID: 21330830 Clinical Trial.
1,527 results